Jump to content
  • Sign Up
Sign in to follow this  

Comparison - Mirvaso with Rhofade

Recommended Posts


Brimonidine (Mirvaso) and oxymetazoline (Rhofade) are both topical α-adrenergic agonists that have been developed to treat the persistent erythema of rosacea patients. Pharmacological profiling showed brimonidine to be highly selective for the α2 adrenergic receptors, whereas oxymetazoline was much less selective with a significant number of off-target activities, including the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor.

As the 5-HT2B receptor is potentially involved in drug-induced valvulopathy, the benefit/risk ratio should be carefully considered, especially in patients with cardiovascular disease or other comorbidities.

Drugs in R&D
March 2018, Volume 18, Issue 1, pp 87–90 | Cite as
In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea
David Piwnica, Atul Pathak, Gregor Schäfer, James R. Docherty

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Create New...